Vertex given neutral rating by Merrill

Merrill Lynch analyst Hari Sambasivam rated Vertex Pharmaceuticals Inc. at neutral. The analyst's estimates for the quarter ended June 30 include revenues of $44.6 million and a pro forma net loss of $62.8 million. During the company's upcoming conference call, Merrill will look for updated financial projections for the remainder of 2006 following the partnership deal for VX-950 and progress of the ongoing enrollment in the Prove 1/ 2 studies. Shares of the Cambridge, Mass.-based biotechnology company were up 56 cents, or 1.57%, at $35.60 on volume of 776,036 shares versus the three-month running average of 1,672,370 shares. (Nasdaq: VRTX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.